ELTX Earnings & Financial Statements
Elicio Therapeutics, Inc.
$1.79
+$0.02(+1.13%)
28
Overall
40
Value
18
Tech
26
Quality
Market Cap
$48.49M
Volume
373.25K
52W Range
$1.71 - $16.00
Target Price
$14.38
ELTX earnings and financial statements: Elicio Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ELTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $2.30M | $28.31M |
| Cost of revenue | - | - | - | - | $433.0K |
| Operating income | -$37.71M | -$44.99M | -$35.74M | -$23.73M | -$39.31M |
| EBITDA | -$37.10M | -$50.21M | -$44.87M | -$30.81M | -$50.04M |
| Net income | -$39.57M | -$51.90M | -$35.20M | -$28.21M | -$54.57M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-12.90 | $-19.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $25.86M | $28.18M | $27.15M | $22.66M | $96.51M |
| Total liabilities | $24.23M | $39.49M | $15.77M | $21.24M | $15.01M |
| Shareholders’ equity | $1.64M | -$11.31M | $11.37M | -$102.14M | $81.51M |
| Cash and equivalents | $18.60M | $17.62M | $12.89M | $6.16M | $88.76M |
| Long-term debt | $13.50M | $25.14M | $6.01M | $6.79M | $3.71M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$36.95M | -$37.07M | -$32.69M | -$22.18M | -$23.94M |
| Capital expenditure | -$16.0K | -$84.0K | -$66.0K | -$654.0K | -$525.4K |
| Free cash flow | -$36.97M | -$37.16M | -$32.76M | -$22.83M | -$24.46M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELTX | $1.79 | +1.1% | 373.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Elicio Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW